How do other countries' key starting materials gain access to the u.s. market? is there a difference compared to the access for active pharmaceutical ingredients?

Question

Accepted Answer

Short answer

Both key starting materials (KSMs) and active pharmaceutical ingredients (APIs) must be produced under U.S. Good Manufacturing Practice (GMP) and are subject to the same import‑control framework (FD&C Act, 21 CFR 310, 21 CFR 312, and 21 CFR 211).
The difference lies mainly in the pre‑market approval that APIs require (IND/NDA, BLA, etc.) and in the level of detail that the U.S. regulator demands from the foreign manufacturer.
KSMs never undergo an IND/NDA review, but they still have to satisfy the same GMP, purity, and safety standards that APIs do, and the importer must prove that the KSM is compliant (e.g., through a Drug Master File, an Import Alert, or a FSVP).

Below is a step‑by‑step outline of the process for a KSM to gain U.S. market access, followed by a comparison with the API pathway.

1. Regulatory context for KSMs

Authority	Key regulation	What it covers
FDA	FD&C Act (21 CFR 310, 312, 211)	Establishes GMP for drug ingredients (both APIs and KSMs).
FDA	Drug Supply Chain Security Act (DSCSA)	Requires importers to verify foreign suppliers (FSVP).
FDA	Import Alert / Import Approval	Specific lists of non‑compliant substances that cannot be imported.
DEA	Controlled Substances Act (CSA)	Applies to KSMs that are controlled substances (e.g., certain intermediates).
EPA/USDA	Environmental/Animal health regulations	For KSMs that are reagents, solvents, or biologics that fall under these agencies.

Bottom line: A KSM is treated as a drug ingredient (not a finished drug). It does not need an IND, NDA, or BLA, but it must meet the same GMP and quality requirements that an API would.

2. Typical path to U.S. market for a foreign KSM

Step	What the importer must do	What the FDA looks for
1. Identify a suitable KSM	Ensure it is the exact chemical (or isomer) needed for API synthesis.	Verify that the KSM’s chemical identity, purity, and safety profile are well‑documented.
2. Establish a foreign supplier	Choose a manufacturer that has a GMP‑certified facility.	Verify facility GMP status via FDA inspection records or third‑party audits.
3. Obtain a Drug Master File (DMF)	The foreign supplier can file a DMF (or a “manufacturing site DMF”) that describes the production process, specifications, impurity profile, etc.	FDA reviews the DMF for adequacy of GMP controls and data.
*4. File a Drug Registration Application* (21 CFR 310.80)**	If the foreign facility is not already registered with FDA, it must file a registration (or the importer must hold an Importer of Record license).	FDA evaluates registration completeness, GMP compliance, and any import alerts.
5. Import‑clearance	The importer must submit the necessary documents (commercial invoice, packing list, certificate of analysis, import license, etc.) at the U.S. port of entry.	FDA may conduct a pre‑clearance inspection or rely on a pre‑approved import route if the KSM is on the FDA’s “approved list.”
6. Post‑import surveillance	The importer must keep records and be ready for FDA inspections.	FDA may inspect the import site, the foreign manufacturing site, or both.

2.1 Foreign Supplier Verification Program (FSVP)

Under the DSCSA, importers must:

Ask Questions, Get Industry Insights … Instantly

Recent Questions

How do other countries' key starting materials gain access to the u.s. market? is there a difference compared to the access for active pharmaceutical ingredients?

1. Regulatory context for KSMs

2. Typical path to U.S. market for a foreign KSM

2.1 Foreign Supplier Verification Program (FSVP)